ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $6,456,896 | -12.2% | 60,221 | 0.0% | 0.01% | -16.7% |
Q4 2022 | $7,354,791 | +22.5% | 60,221 | +3.6% | 0.01% | +20.0% |
Q3 2022 | $6,002,000 | +26.2% | 58,127 | +13.6% | 0.01% | +42.9% |
Q2 2022 | $4,757,000 | -18.5% | 51,174 | +1.7% | 0.01% | -12.5% |
Q1 2022 | $5,836,000 | +17.4% | 50,305 | +36.2% | 0.01% | +33.3% |
Q4 2021 | $4,970,000 | -11.5% | 36,943 | +4.8% | 0.01% | -33.3% |
Q3 2021 | $5,618,000 | +87.5% | 35,248 | +54.7% | 0.01% | +125.0% |
Q2 2021 | $2,997,000 | +10.4% | 22,780 | +8.2% | 0.00% | 0.0% |
Q1 2021 | $2,714,000 | -57.1% | 21,057 | -44.4% | 0.00% | 0.0% |
Q4 2020 | $6,320,000 | +105.5% | 37,894 | +95.5% | 0.00% | -20.0% |
Q3 2020 | $3,076,000 | +17.3% | 19,388 | +9.4% | 0.01% | 0.0% |
Q2 2020 | $2,622,000 | +52.4% | 17,729 | +21.9% | 0.01% | +25.0% |
Q1 2020 | $1,720,000 | -14.7% | 14,538 | +0.3% | 0.00% | +33.3% |
Q4 2019 | $2,016,000 | +44.6% | 14,492 | 0.0% | 0.00% | +50.0% |
Q3 2019 | $1,394,000 | – | 14,492 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |